Annual EBIT
-$14.58 M
+$5.21 M+26.32%
December 31, 2023
Summary
- As of February 26, 2025, MRKR annual earnings before interest & taxes is -$14.58 million, with the most recent change of +$5.21 million (+26.32%) on December 31, 2023.
- During the last 3 years, MRKR annual EBIT has risen by +$13.84 million (+48.69%).
- MRKR annual EBIT is now -3738.22% below its all-time high of -$379.90 thousand, reached on December 31, 2001.
Performance
MRKR EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$2.40 M
-$91.80 K-3.98%
September 30, 2024
Summary
- As of February 26, 2025, MRKR quarterly earnings before interest & taxes is -$2.40 million, with the most recent change of -$91.80 thousand (-3.98%) on September 30, 2024.
- Over the past year, MRKR quarterly EBIT has dropped by -$91.80 thousand (-3.98%).
- MRKR quarterly EBIT is now -125.28% below its all-time high of $9.49 million, reached on December 31, 2009.
Performance
MRKR Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$10.19 M
+$800.10 K+7.28%
September 30, 2024
Summary
- As of February 26, 2025, MRKR TTM earnings before interest & taxes is -$10.19 million, with the most recent change of +$800.10 thousand (+7.28%) on September 30, 2024.
- Over the past year, MRKR TTM EBIT has increased by +$800.10 thousand (+7.28%).
- MRKR TTM EBIT is now -222.23% below its all-time high of $8.34 million, reached on December 31, 2009.
Performance
MRKR TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
MRKR EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +26.3% | -4.0% | +7.3% |
| 3 y3 years | +48.7% | -4.0% | +7.3% |
| 5 y5 years | +90.2% | +59.3% | +56.3% |
MRKR EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +63.1% | -4.0% | +75.5% | at high | +74.8% |
| 5 y | 5-year | at high | +63.1% | -4.0% | +78.0% | at high | +74.8% |
| alltime | all time | -3738.2% | +90.2% | -125.3% | +98.2% | -222.2% | +93.3% |
Marker Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$2.40 M(+4.0%) | -$10.19 M(-7.3%) |
| Jun 2024 | - | -$2.31 M(-9.5%) | -$10.99 M(-14.2%) |
| Mar 2024 | - | -$2.55 M(-13.2%) | -$12.82 M(-12.1%) |
| Dec 2023 | -$14.58 M(-26.3%) | -$2.94 M(-8.2%) | -$14.58 M(-0.7%) |
| Sep 2023 | - | -$3.20 M(-22.6%) | -$14.68 M(-15.2%) |
| Jun 2023 | - | -$4.13 M(-4.1%) | -$17.31 M(-6.2%) |
| Mar 2023 | - | -$4.31 M(+41.8%) | -$18.44 M(-22.9%) |
| Dec 2022 | -$19.79 M(-49.9%) | -$3.04 M(-47.8%) | -$23.93 M(-21.9%) |
| Sep 2022 | - | -$5.83 M(+10.6%) | -$30.65 M(-12.0%) |
| Jun 2022 | - | -$5.27 M(-46.2%) | -$34.85 M(-13.9%) |
| Mar 2022 | - | -$9.79 M(+0.3%) | -$40.49 M(+2.6%) |
| Dec 2021 | -$39.48 M(+38.9%) | -$9.76 M(-2.6%) | -$39.48 M(+3.3%) |
| Sep 2021 | - | -$10.02 M(-8.1%) | -$38.22 M(+7.4%) |
| Jun 2021 | - | -$10.91 M(+24.2%) | -$35.57 M(+16.4%) |
| Mar 2021 | - | -$8.78 M(+3.2%) | -$30.56 M(+7.5%) |
| Dec 2020 | -$28.42 M(+27.4%) | -$8.51 M(+15.4%) | -$28.42 M(+13.4%) |
| Sep 2020 | - | -$7.38 M(+25.2%) | -$25.06 M(+7.4%) |
| Jun 2020 | - | -$5.89 M(-11.3%) | -$23.34 M(+0.1%) |
| Mar 2020 | - | -$6.64 M(+29.0%) | -$23.32 M(+4.5%) |
| Dec 2019 | -$22.32 M(-84.9%) | -$5.15 M(-8.9%) | -$22.32 M(-85.4%) |
| Sep 2019 | - | -$5.65 M(-3.7%) | -$153.04 M(+0.8%) |
| Jun 2019 | - | -$5.87 M(+4.2%) | -$151.81 M(+0.9%) |
| Mar 2019 | - | -$5.64 M(-95.9%) | -$150.41 M(+1.6%) |
| Dec 2018 | -$147.97 M(+1209.8%) | -$135.87 M(+2968.2%) | -$147.97 M(+901.5%) |
| Sep 2018 | - | -$4.43 M(-0.9%) | -$14.77 M(+4.4%) |
| Jun 2018 | - | -$4.47 M(+39.7%) | -$14.15 M(+17.2%) |
| Mar 2018 | - | -$3.20 M(+19.3%) | -$12.08 M(+6.9%) |
| Dec 2017 | -$11.30 M(+36.7%) | -$2.68 M(-29.6%) | -$11.30 M(+10.7%) |
| Sep 2017 | - | -$3.81 M(+59.1%) | -$10.21 M(+11.9%) |
| Jun 2017 | - | -$2.39 M(-1.0%) | -$9.12 M(+2.2%) |
| Mar 2017 | - | -$2.42 M(+51.9%) | -$8.92 M(+8.0%) |
| Dec 2016 | -$8.26 M(-75.7%) | -$1.59 M(-41.5%) | -$8.26 M(-77.6%) |
| Sep 2016 | - | -$2.72 M(+24.0%) | -$36.82 M(+2.7%) |
| Jun 2016 | - | -$2.19 M(+25.1%) | -$35.84 M(+3.0%) |
| Mar 2016 | - | -$1.75 M(-94.2%) | -$34.78 M(+2.1%) |
| Dec 2015 | -$34.06 M(+12.4%) | -$30.15 M(+1634.8%) | -$34.06 M(+633.8%) |
| Sep 2015 | - | -$1.74 M(+52.7%) | -$4.64 M(+4.2%) |
| Jun 2015 | - | -$1.14 M(+10.7%) | -$4.46 M(+74.4%) |
| Mar 2015 | - | -$1.03 M(+39.6%) | -$2.56 M(-91.7%) |
| Dec 2014 | -$30.31 M(+702.6%) | -$736.50 K(-52.6%) | -$30.72 M(-6.3%) |
| Sep 2014 | - | -$1.55 M(-303.7%) | -$32.77 M(+4.0%) |
| Jun 2014 | - | $762.10 K(-102.6%) | -$31.52 M(-4.1%) |
| Mar 2014 | - | -$29.19 M(+944.9%) | -$32.86 M(+770.2%) |
| Dec 2013 | -$3.78 M(-30.4%) | -$2.79 M(+841.8%) | -$3.78 M(+39.7%) |
| Sep 2013 | - | -$296.60 K(-48.8%) | -$2.70 M(-8.7%) |
| Jun 2013 | - | -$579.60 K(+444.2%) | -$2.96 M(-41.2%) |
| Mar 2013 | - | -$106.50 K(-93.8%) | -$5.03 M(-7.3%) |
| Dec 2012 | -$5.43 M | -$1.72 M(+210.8%) | -$5.42 M(+67.7%) |
| Sep 2012 | - | -$553.30 K(-79.1%) | -$3.24 M(-5.5%) |
| Jun 2012 | - | -$2.65 M(+428.1%) | -$3.42 M(+217.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | -$501.80 K(-206.8%) | -$1.08 M(-18.3%) |
| Dec 2011 | -$1.35 M(-41.1%) | $469.80 K(-163.4%) | -$1.32 M(+48.6%) |
| Sep 2011 | - | -$740.50 K(+141.8%) | -$888.70 K(+26.3%) |
| Jun 2011 | - | -$306.30 K(-58.8%) | -$703.60 K(-55.1%) |
| Mar 2011 | - | -$743.60 K(-182.5%) | -$1.57 M(-31.6%) |
| Dec 2010 | -$2.29 M(-45.4%) | $901.70 K(-262.4%) | -$2.29 M(-136.4%) |
| Sep 2010 | - | -$555.40 K(-52.5%) | $6.30 M(-1.3%) |
| Jun 2010 | - | -$1.17 M(-20.4%) | $6.39 M(-10.8%) |
| Mar 2010 | - | -$1.47 M(-115.5%) | $7.16 M(-14.2%) |
| Dec 2009 | -$4.19 M(+179.5%) | $9.49 M(-2116.3%) | $8.34 M(-430.7%) |
| Sep 2009 | - | -$470.90 K(+18.6%) | -$2.52 M(-19.6%) |
| Jun 2009 | - | -$396.90 K(+38.6%) | -$3.14 M(-15.1%) |
| Mar 2009 | - | -$286.40 K(-79.1%) | -$3.69 M(-4.5%) |
| Dec 2008 | -$1.50 M(-40.3%) | -$1.37 M(+26.0%) | -$3.87 M(+14.4%) |
| Sep 2008 | - | -$1.09 M(+13.9%) | -$3.38 M(+20.8%) |
| Jun 2008 | - | -$953.00 K(+106.1%) | -$2.80 M(+4.0%) |
| Mar 2008 | - | -$462.30 K(-47.5%) | -$2.69 M(+7.1%) |
| Dec 2007 | -$2.51 M(+182.7%) | -$880.70 K(+75.3%) | -$2.51 M(+31.9%) |
| Sep 2007 | - | -$502.40 K(-40.5%) | -$1.90 M(+9.9%) |
| Jun 2007 | - | -$845.00 K(+198.3%) | -$1.73 M(+65.1%) |
| Mar 2007 | - | -$283.30 K(+3.4%) | -$1.05 M(+18.2%) |
| Dec 2006 | -$888.20 K(+1.8%) | -$273.90 K(-17.1%) | -$888.20 K(+63.1%) |
| Sep 2006 | - | -$330.20 K(+103.6%) | -$544.60 K(+3.4%) |
| Jun 2006 | - | -$162.20 K(+33.1%) | -$526.80 K(-36.1%) |
| Mar 2006 | - | -$121.90 K(-274.9%) | -$824.30 K(-5.2%) |
| Dec 2005 | -$872.70 K(-66.3%) | $69.70 K(-122.3%) | -$869.90 K(-55.2%) |
| Sep 2005 | - | -$312.40 K(-32.0%) | -$1.94 M(-4.3%) |
| Jun 2005 | - | -$459.70 K(+174.4%) | -$2.03 M(-2.9%) |
| Mar 2005 | - | -$167.50 K(-83.3%) | -$2.09 M(-19.4%) |
| Dec 2004 | -$2.59 M(-55.2%) | -$1.00 M(+150.5%) | -$2.59 M(-38.6%) |
| Sep 2004 | - | -$399.40 K(-23.4%) | -$4.22 M(-12.3%) |
| Jun 2004 | - | -$521.30 K(-22.2%) | -$4.81 M(-13.6%) |
| Mar 2004 | - | -$669.70 K(-74.5%) | -$5.57 M(-3.5%) |
| Dec 2003 | -$5.78 M(+152.9%) | -$2.63 M(+164.9%) | -$5.78 M(+34.7%) |
| Sep 2003 | - | -$993.10 K(-22.4%) | -$4.29 M(+11.6%) |
| Jun 2003 | - | -$1.28 M(+46.4%) | -$3.85 M(+8.1%) |
| Mar 2003 | - | -$874.60 K(-23.5%) | -$3.56 M(+22.0%) |
| Dec 2002 | -$2.28 M(+501.4%) | -$1.14 M(+109.2%) | -$2.92 M(+60.9%) |
| Sep 2002 | - | -$546.60 K(-44.9%) | -$1.81 M(+37.1%) |
| Jun 2002 | - | -$992.30 K(+326.4%) | -$1.32 M(+288.2%) |
| Mar 2002 | - | -$232.70 K(+487.6%) | -$340.40 K(-10.4%) |
| Dec 2001 | -$379.90 K(-17.5%) | -$39.60 K(-30.2%) | -$379.80 K(-209.4%) |
| Sep 2001 | - | -$56.70 K(+397.4%) | $347.30 K(-687.6%) |
| Jun 2001 | - | -$11.40 K(-95.8%) | -$59.10 K(-49.1%) |
| Mar 2001 | - | -$272.10 K(-139.6%) | -$116.20 K(-18.6%) |
| Dec 2000 | -$460.50 K(-56.7%) | $687.50 K(-248.5%) | -$142.70 K(-82.8%) |
| Sep 2000 | - | -$463.10 K(+576.1%) | -$830.20 K(+126.2%) |
| Jun 2000 | - | -$68.50 K(-77.1%) | -$367.10 K(+22.9%) |
| Mar 2000 | - | -$298.60 K | -$298.60 K |
| Dec 1999 | -$1.06 M | - | - |
FAQ
- What is Marker Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Marker Therapeutics?
- What is Marker Therapeutics annual EBIT year-on-year change?
- What is Marker Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Marker Therapeutics?
- What is Marker Therapeutics quarterly EBIT year-on-year change?
- What is Marker Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Marker Therapeutics?
- What is Marker Therapeutics TTM EBIT year-on-year change?
What is Marker Therapeutics annual earnings before interest & taxes?
The current annual EBIT of MRKR is -$14.58 M
What is the all time high annual EBIT for Marker Therapeutics?
Marker Therapeutics all-time high annual earnings before interest & taxes is -$379.90 K
What is Marker Therapeutics annual EBIT year-on-year change?
Over the past year, MRKR annual earnings before interest & taxes has changed by +$5.21 M (+26.32%)
What is Marker Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of MRKR is -$2.40 M
What is the all time high quarterly EBIT for Marker Therapeutics?
Marker Therapeutics all-time high quarterly earnings before interest & taxes is $9.49 M
What is Marker Therapeutics quarterly EBIT year-on-year change?
Over the past year, MRKR quarterly earnings before interest & taxes has changed by -$91.80 K (-3.98%)
What is Marker Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of MRKR is -$10.19 M
What is the all time high TTM EBIT for Marker Therapeutics?
Marker Therapeutics all-time high TTM earnings before interest & taxes is $8.34 M
What is Marker Therapeutics TTM EBIT year-on-year change?
Over the past year, MRKR TTM earnings before interest & taxes has changed by +$800.10 K (+7.28%)